 A Phase 12a, open-label, dose-escalation study with enrollment in Phase 1 to continue until determination of the Maximum Tolerated Dose MTD Recommended Phase 2a Dose RP2D, and then enrollment into Phase 2a expansion cohorts will be initiated. 